These agents are designed to deliver cytotoxic radiation directly to prostate cancer cells via a therapeutic payload (a radionuclide emitting beta or alpha radiation) connected to a targeting vector which binds specifically to PSMA. This evidence concerns the gene FOLH1 and prostate carcinoma.